Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

KRAS Mutant Non-Small Cell Lung Cancer × palbociclib × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Advanced Solid Tumors 2 Solid Tumors Refractory to Standard Therapy 1 Solid Tumors 1 Solid Tumor, Adult 1 Solid Tumor 1 Malignant Female Reproductive System Neoplasm 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Advanced Solid Tumor 1

Interventions

palbociclib 1 mirdametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed

Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡